Omadacycline
Based on 33 publication(s) in Google Scholar
Omadacycline (PTK 0796), a first-in-class orally active aminomethylcycline antibacterial, is a member of the tetracycline class of antibiotics. Omadacycline acts through the inhibition of bacterial protein synthesis by binding to the 30S ribosomal subunit. Omadacycline possesses broad-spectrum antibacterial activity against aerobic and anaerobic Gram-positive and Gram-negative bacteria, as well as atypical bacteria. Omadacycline can be used for the research of acute bacterial skin and skin-structure infections, community-acquired pneumonia, and urinary tract infections.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.85%
- No. CAS: 389139-89-3
- Fòrmula: C29H40N4O7
- Peso molecular:556.65
-
Almacenamiento:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Rare Diseases Drug Library
HY-L102
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Omadacycline
More- Nat Microbiol. 2026 Feb 6. [Abstract]
- Nat Microbiol. 2023 Mar;8(3):410-423. [Abstract]
- Nat Struct Mol Biol. 2023 Sep;30(9):1380-1392. [Abstract]
- PLoS Biol. 2022 Sep 28;20(9):e3001808. [Abstract]
- Virulence. 2022 Dec;13(1):77-88. [Abstract]
- J Clin Microbiol. 2020 Jan 28;58(2):e01603-19. [Abstract]
- Antibiotics (Basel). 2022 Sep 23;11(10):1298. [Abstract]
- Ann Lab Med. 2021 May 1;41(3):293-301. [Abstract]
- Antimicrob Agents Chemother. 2025 May 23:e0024925. [Abstract]
- Antimicrob Agents Chemother. 2024 Oct 29:e0105124. [Abstract]
- Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0063824. [Abstract]
- Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0145922. [Abstract]
- Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02097-19. [Abstract]
- Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00470-19. [Abstract]
- Microbiol Spectr. 2023 Jun 15;11(3):e0071823. [Abstract]
- Microbiol Spectr. 2023 Feb 14;11(1):e0323822. [Abstract]
- J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. [Abstract]
- J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. [Abstract]
- Pathology. 2026 Feb 6:S0031-3025(26)00393-4. [Abstract]
- J Microbiol Immunol Infect. 2025 Apr;58(2):219-225. [Abstract]
- Open Forum Infect Dis. 2024 Oct 11;11(11):ofae611. [Abstract]
- J Glob Antimicrob Resist. 2025 Aug 8:44:435-441. [Abstract]
- Malar J. 2025 Jun 19;24(1):194. [Abstract]
- Infect Drug Resist. 2025 Oct 4:18:5239-5247. [Abstract]
- Animal Feed Science and Technology. 2014 Dec;198:323-332.
- J Antibiot (Tokyo). 2026 May 27. [Abstract]
- J Antibiot (Tokyo). 2022 Aug;75(8):463-471. [Abstract]
- Clin Exp Pharmacol Physiol. 2023 Jul;50(7):604-609. [Abstract]
- Diagn Micr Infec Dis. 2020 Nov;98(3):115129. [Abstract]
- bioRxiv. 2026 Jan 14.
- Cureus. 2024 Dec 1;16(12):e74917. [Abstract]
- Comput Intell Neurosci. 2022 Apr 25;2022:7636983. [Abstract]
- Research Square Preprint. 2020 Jun.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
Ver todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
|
Tetracycline |
Omadacycline displays activity against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), beta-hemolytic streptococci, penicillin-resistant Streptococcus pneumonia (PRSP) and Haemophilus influenzae (H. influenzae), with MIC90s of 1.0, 0.25, 0.5, 0.25 and 2.0 μg/mL respectively[2].
Omadacycline is active against strains expressing tetracycline and other antibiotics resistance by ribosomal protection and active tetracycline efflux[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 389139-89-3
-
Appearance Solid
-
Peso molecular 556.65
-
Fòrmula C29H40N4O7
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(O)[C@@H](N(C)C)[C@@](C[C@@]2([H])C(C(C3=C(O)C(CNCC(C)(C)C)=CC(N(C)C)=C3C2)=O)=C4O)([H])[C@@]4(O)C1=O)N
-
Synonyms
PTK 0796; Amadacycline
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (33)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Addendum: ESKAPE pathogens rapidly develop resistance against antibiotics in development in vitro. [Abstract]2026 Feb 6. PMID: 41652022 -
Nat Microbiol
Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]2023 Mar;8(3):410-423. PMID: 36759752 -
Nat Struct Mol Biol
2023 Sep;30(9):1380-1392. PMID: 37550453 -
PLoS Biol
Low levels of tetracyclines select for a mutation that prevents the evolution of high-level resistance to tigecycline. [Abstract]2022 Sep 28;20(9):e3001808. PMID: 36170241 -
Virulence
MALDI-TOF MS for rapid detection and differentiation between Tet(X)-producers and non-Tet(X)-producing tetracycline-resistant Gram-negative bacteria. [Abstract]2022 Dec;13(1):77-88. PMID: 34951562 -
J Clin Microbiol
Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole. [Abstract]2020 Jan 28;58(2):e01603-19. PMID: 31748318 -
Antibiotics (Basel)
Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates. [Abstract]2022 Sep 23;11(10):1298. PMID: 36289956 -
Ann Lab Med
In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis. [Abstract]2021 May 1;41(3):293-301. PMID: 33303714 -
Antimicrob Agents Chemother
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]2025 May 23:e0024925. PMID: 40407337 -
Antimicrob Agents Chemother
Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus. [Abstract]2024 Oct 29:e0105124. PMID: 39470195 -
Antimicrob Agents Chemother
Omadacycline powder for research procured from unauthorized commercial vendors may be impure and/or unstable. [Abstract]2024 Jul 9;68(7):e0063824. PMID: 38888320 -
Antimicrob Agents Chemother
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. [Abstract]2023 Feb 16;67(2):e0145922. PMID: 36688684 -
Antimicrob Agents Chemother
Omadacycline Efficacy against Enterococcus faecalis Isolated in China: In Vitro Activity, Heteroresistance, and Resistance Mechanisms. [Abstract]2020 Feb 21;64(3):e02097-19. PMID: 31871086 -
Antimicrob Agents Chemother
In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus. [Abstract]2019 May 24;63(6). pii: e00470-19. PMID: 30962331 -
Microbiol Spectr
Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro. [Abstract]2023 Jun 15;11(3):e0071823. PMID: 37140428 -
Microbiol Spectr
In Vitro Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria. [Abstract]2023 Feb 14;11(1):e0323822. PMID: 36475850
Omadacycline purchased from MedChemExpress. Usage Cited in: Microbiol Spectr. 2023 Feb 14;11(1):e0323822. [Abstract]
The MIC distributions of Omadacycline against 43 M. fortuitum isolates. The y axis shows the number of strains with each MIC value, with the specific numbers shown above the bars.
-
J Antimicrob Chemother
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]2021 Jul 15;76(8):2071-2078. PMID: 33956969 -
J Antimicrob Chemother
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]2021 Feb 11;76(3):653-658. PMID: 33258923 -
Pathology
In vitro activity of recently introduced Gram-positive-specific antimicrobial agents against Australian methicillin-resistant Staphylococcus aureus isolates. [Abstract]2026 Feb 6:S0031-3025(26)00393-4. PMID: 41760492 -
J Microbiol Immunol Infect
Antimicrobial resistance among imipenem-non-susceptible Escherichia coli and Klebsiella pneumoniae isolates, with an emphasis on novel β-lactam/β-lactamase inhibitor combinations and tetracycline derivatives: The Taiwan surveillance of antimicrobial resistance program, 2020-2022. [Abstract]2025 Apr;58(2):219-225. PMID: 39934015 -
Open Forum Infect Dis
Successful Treatment of Recurrent Extensively Drug-Resistant Elizabethkingia anophelis Bacteremia Secondary to Ventricular Assist Device-Associated Infection. [Abstract]2024 Oct 11;11(11):ofae611. PMID: 39494452 -
J Glob Antimicrob Resist
Susceptibility of multidrug-resistant Escherichia coli and Klebsiella pneumoniae to oral antibiotics in Australia. [Abstract]2025 Aug 8:44:435-441. PMID: 40784378 -
Malar J
2025 Jun 19;24(1):194. PMID: 40537756 -
Infect Drug Resist
In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus. [Abstract]2025 Oct 4:18:5239-5247. PMID: 41069760 -
-
J Antibiot (Tokyo)
Combined effect of eravacycline and omadacycline with other antimicrobial agents against Acinetobacter Baumannii. [Abstract]2026 May 27. PMID: 42204275 -
J Antibiot (Tokyo)
Comparison of antibacterial activities and resistance mechanisms of omadacycline and tigecycline against Enterococcus faecium. [Abstract]2022 Aug;75(8):463-471. PMID: 35760902 -
Clin Exp Pharmacol Physiol
In vitro susceptibility testing of tetracycline-class antibiotics against slowly growing non-tuberculous mycobacteria. [Abstract]2023 Jul;50(7):604-609. PMID: 37086075 -
Diagn Micr Infec Dis
In vitro activity of new tetracycline analogues omadacycline and eravacycline against clinical isolates of Helicobacter pylori collected in China. [Abstract]2020 Nov;98(3):115129. PMID: 32739761 -
-
Cureus
2024 Dec 1;16(12):e74917. PMID: 39742159 -
Comput Intell Neurosci
Omadacycline Efficacy against Streptococcus Agalactiae Isolated in China: Correlation between Resistance and Virulence Gene and Biofilm Formation. [Abstract]2022 Apr 25;2022:7636983. PMID: 35510054 -
Solvente y solubilidad
Methanol : 125 mg/mL (224.56 mM; Need ultrasonic)
DMSO : 100 mg/mL (179.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (8.98 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Durães F, et, al. Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines. Pharmaceuticals (Basel). 2019 Apr 21;12(2):63. [Content Brief]
[2]. Macone AB, et, al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;58(2):1127-35. [Content Brief]
[3]. Zhanel GG, et, al. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs. 2020 Feb;80(3):285-313. [Content Brief]
[4]. Markham A, et, al. Omadacycline: First Global Approval. Drugs. 2018 Dec;78(18):1931-1937. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / Methanol | 1 mM | 1.7965 mL | 8.9823 mL | 17.9646 mL | 44.9115 mL |
| 5 mM | 0.3593 mL | 1.7965 mL | 3.5929 mL | 8.9823 mL | |
| 10 mM | 0.1796 mL | 0.8982 mL | 1.7965 mL | 4.4912 mL | |
| 15 mM | 0.1198 mL | 0.5988 mL | 1.1976 mL | 2.9941 mL | |
| 20 mM | 0.0898 mL | 0.4491 mL | 0.8982 mL | 2.2456 mL | |
| 25 mM | 0.0719 mL | 0.3593 mL | 0.7186 mL | 1.7965 mL | |
| 30 mM | 0.0599 mL | 0.2994 mL | 0.5988 mL | 1.4971 mL | |
| 40 mM | 0.0449 mL | 0.2246 mL | 0.4491 mL | 1.1228 mL | |
| 50 mM | 0.0359 mL | 0.1796 mL | 0.3593 mL | 0.8982 mL | |
| 60 mM | 0.0299 mL | 0.1497 mL | 0.2994 mL | 0.7485 mL | |
| 80 mM | 0.0225 mL | 0.1123 mL | 0.2246 mL | 0.5614 mL | |
| 100 mM | 0.0180 mL | 0.0898 mL | 0.1796 mL | 0.4491 mL |
Omadacycline Related Classifications
HY-14865 Related Classifications
Powered by Bioz